These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 21365219

  • 1. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G.
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [Abstract] [Full Text] [Related]

  • 2. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.
    Cancer; 2011 Jun 01; 117(11):2419-25. PubMed ID: 24048789
    [Abstract] [Full Text] [Related]

  • 3. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.
    Eur J Cancer; 2012 Nov 01; 48(16):2993-3000. PubMed ID: 22677260
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 01; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 5. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W.
    Urol Int; 2007 Oct 01; 79(4):307-11. PubMed ID: 18025847
    [Abstract] [Full Text] [Related]

  • 6. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
    Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM.
    Clin Genitourin Cancer; 2012 Mar 01; 10(1):6-14. PubMed ID: 22340631
    [Abstract] [Full Text] [Related]

  • 7. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.
    Cancer; 2007 Aug 01; 110(3):556-63. PubMed ID: 17577218
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
    Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ.
    Cancer Chemother Pharmacol; 2011 Apr 01; 67(4):927-33. PubMed ID: 20602233
    [Abstract] [Full Text] [Related]

  • 9. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM.
    Cancer; 2007 Sep 01; 110(5):996-1002. PubMed ID: 17639587
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):17-21. PubMed ID: 16721549
    [Abstract] [Full Text] [Related]

  • 11. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
    Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P.
    Anticancer Res; 2012 Aug 01; 32(8):3305-9. PubMed ID: 22843906
    [Abstract] [Full Text] [Related]

  • 12. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G.
    J Clin Oncol; 2011 Jun 01; 29(16):2191-8. PubMed ID: 21483004
    [Abstract] [Full Text] [Related]

  • 13. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ.
    Clin Cancer Res; 2008 Oct 01; 14(19):6270-6. PubMed ID: 18829508
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B 99813.
    Cancer; 2003 Dec 15; 98(12):2592-8. PubMed ID: 14669278
    [Abstract] [Full Text] [Related]

  • 15. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F, Ruether D, Ernst S, North S, Cheng T, Perrotte P, Karakiewicz P, Winquist E, Canadian Uro-Oncology Group.
    BJU Int; 2008 Aug 05; 102(5):551-5. PubMed ID: 18510661
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.
    Polyzos A, Tsavaris N, Kosmas C, Polyzos K, Giannopoulos A, Felekouras E, Nikiteas N, Kouraklis G, Griniatsos J, Safioleas M, Stamatakos M, Pikoulis E, Papachristodoulou A, Gogas H.
    Anticancer Res; 2006 Aug 05; 26(5B):3749-53. PubMed ID: 17094396
    [Abstract] [Full Text] [Related]

  • 18. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK, Prostate Cancer Clinical Trials Consortium.
    Cancer; 2008 Feb 01; 112(3):521-6. PubMed ID: 18085595
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
    Takaha N, Okihara K, Kamoi K, Hongo F, Iwata T, Yano K, Ueda T, Takeuchi I, Yamada T, Kawauchi A, Miki T.
    Urol Int; 2011 Feb 01; 87(3):263-9. PubMed ID: 21876321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.